Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Procter’s Annual Medical Device Series

Summary

Speakers

Raymond C. Zemlin

Related Content

Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2024-2025

Biocon Announces FDA Approval of Ustekinumab Biosimilar

Update on Pending Denosumab BPCIA Litigations

Preliminary Injunction Halts Corporate Transparency Act Enforcement: What You Need to Know

European Commission Approves Samsung Bioepis and Biogen’s Aflibercept Biosimilar

FDA approves CAR-T Cell Therapy for Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Corporate Transparency Act: January 1 Deadline is Almost Here

Amgen Files BPCIA Complaint Against Accord Biopharma Regarding Denosumab Biosimilar

Goodwin CLE Week 2025

AQEMIA Raises $38 Million

Goodwin: The Destination Life Sciences M&A Firm

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Goodwin Advises Ampersand Capital Partners in Acquisition of Nektar Therapeutics’ PEG Supply Business and Manufacturing Facility

Goodwin Advised Nuvig Therapeutics on $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator

Goodwin Advises Tubulis on Exclusive Option and License Agreement with Gilead to Develop ADC Candidate for Select Solid Tumor Target for $20 Million Upfront and up to $445 Million in Additional Payments

Goodwin Advises Relay Therapeutics in Exclusive Global License Agreement with Elevar Therapeutics for up to $75 Million Upfront and in Regulatory Milestones and up to $425 Million in Commercial Milestones

Life Sciences